Live feed16:01:00·737dPRReleasevia QuantisnowAdaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor IndicationsByQuantisnow·Wall Street's wire, on your screen.ADAP· Adaptimmune Therapeutics plcGLPG· Galapagos NVHealth Care